Medtronic PLC $MDT Holdings Trimmed by M&G PLC

M&G PLC lowered its holdings in Medtronic PLC (NYSE:MDT) by 7.5% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,842,222 shares of the medical technology company’s stock after selling 230,247 shares during the period. Medtronic makes up 1.4% of M&G PLC’s portfolio, making the stock its 16th biggest position. M&G PLC’s holdings in Medtronic were worth $270,011,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Corundum Trust Company INC purchased a new position in Medtronic during the 3rd quarter valued at about $27,000. Valley Wealth Managers Inc. purchased a new position in Medtronic during the third quarter valued at approximately $29,000. Delos Wealth Advisors LLC acquired a new position in Medtronic in the 2nd quarter valued at approximately $27,000. Steigerwald Gordon & Koch Inc. purchased a new stake in Medtronic in the 3rd quarter worth approximately $33,000. Finally, Tripletail Wealth Management LLC acquired a new stake in shares of Medtronic during the 3rd quarter valued at $34,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Medtronic Stock Down 1.3%

Shares of MDT stock opened at $99.57 on Monday. The stock’s 50 day simple moving average is $99.28 and its 200 day simple moving average is $96.46. Medtronic PLC has a twelve month low of $79.55 and a twelve month high of $106.33. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42. The company has a market capitalization of $127.65 billion, a price-to-earnings ratio of 26.84, a PEG ratio of 2.62 and a beta of 0.71.

Medtronic (NYSE:MDT) last announced its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, beating the consensus estimate of $1.31 by $0.05. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The company had revenue of $8.96 billion for the quarter, compared to the consensus estimate of $8.86 billion. During the same quarter last year, the company posted $1.26 earnings per share. The company’s revenue for the quarter was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, research analysts predict that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, January 16th. Investors of record on Friday, December 26th were paid a $0.71 dividend. The ex-dividend date was Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a yield of 2.9%. Medtronic’s dividend payout ratio (DPR) is presently 76.55%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the stock. Daiwa Securities Group upped their price target on shares of Medtronic from $104.00 to $117.00 and gave the stock a “buy” rating in a research note on Tuesday, November 25th. Wall Street Zen raised Medtronic from a “hold” rating to a “buy” rating in a research report on Friday, January 23rd. Barclays assumed coverage on Medtronic in a research note on Friday. They set an “overweight” rating and a $116.00 price target for the company. Truist Financial lowered their price target on Medtronic from $110.00 to $107.00 and set a “hold” rating for the company in a research note on Thursday, December 18th. Finally, TD Cowen restated a “buy” rating on shares of Medtronic in a report on Friday, November 14th. Sixteen analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $111.21.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: FDA cleared Medtronic’s Stealth AXiS system — an integrated planning, navigation and robotics platform for spine surgery that expands the company’s procedural addressable market and supports hardware/software recurring revenue potential. This is a material product‑launch catalyst for spine and future cranial/ENT applications. PR Newswire
• Positive Sentiment: Independent coverage and price‑target lifts: Barclays initiated coverage with an Overweight and $116 PT, and Needham upgraded to Buy with a $121 PT — both signal analyst conviction that recent product momentum and margins support upside from current levels. Benzinga Needham Upgrade
• Positive Sentiment: Market commentary highlights improving returns/operational momentum that could support multiple expansion if sustained — a constructive narrative for longer‑term investors. Yahoo Finance
• Neutral Sentiment: Q3 FY2026 earnings preview: analysts outline what to watch in the upcoming report (revenue cadence, procedure volumes, and guidance) — an event that could be a short‑term catalyst but not new information. MSN Earnings Preview
• Neutral Sentiment: Dividend/income writeups underscore MDT’s ~2.8% yield and ways to generate cash flow; supportive for income investors but a limited driver of near‑term price moves. Benzinga Dividend
• Negative Sentiment: Geopolitical and China exposure risks: analysis highlights tariffs and China’s volume‑based procurement (VBP) program as potential headwinds to margins and growth in a key market — a meaningful downside risk that can compress near‑term revenue and investor sentiment. Seeking Alpha

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).